NEUROD6

Across TCGA pan-cancer cohorts, NEUROD6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NEUROD6 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NEUROD6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NEUROD6 expression acts as an unfavorable survival marker.

STAD, KIRP, and UCEC are the cancer types where NEUROD6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.688	<.001	36	view →
KIRP	OS	Median	All	0.571	0.904	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	II,III,IV	0.179	0.731	<.001	6	view →
LUAD	OS	Median	All	0.277	0.787	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NEUROD6–STAD (OS)

Open the STAD breakdown →